Total Payments
$206,240
2024 Payments
$39,910
Companies
32
Transactions
1,193
Medicare Patients
336
Medicare Billing
$57,531
Payment Breakdown by Category
Other$174,225 (84.5%)
Food & Beverage$19,643 (9.5%)
Travel$11,290 (5.5%)
Consulting$960.00 (0.5%)
Education$122.15 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $171,475 | 117 | 83.1% |
| Food and Beverage | $19,643 | 928 | 9.5% |
| Travel and Lodging | $11,290 | 134 | 5.5% |
| Honoraria | $2,750 | 1 | 1.3% |
| Consulting Fee | $960.00 | 2 | 0.5% |
| Education | $122.15 | 11 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $106,999 | 319 | $0 (2024) |
| Allergan, Inc. | $53,856 | 152 | $0 (2020) |
| ABBVIE INC. | $30,608 | 91 | $0 (2024) |
| Corium, LLC | $3,195 | 27 | $0 (2024) |
| Tris Pharma Inc | $1,789 | 89 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $938.71 | 53 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $884.75 | 42 | $0 (2024) |
| Lundbeck LLC | $821.49 | 51 | $0 (2024) |
| Neuronetics, Inc. | $785.90 | 30 | $0 (2023) |
| Neos Therapeutics, LP | $759.76 | 38 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,910 | 222 | Supernus Pharmaceuticals, Inc. ($26,968) |
| 2023 | $46,504 | 192 | Supernus Pharmaceuticals, Inc. ($22,507) |
| 2022 | $36,244 | 191 | Supernus Pharmaceuticals, Inc. ($34,686) |
| 2021 | $24,422 | 162 | Supernus Pharmaceuticals, Inc. ($22,837) |
| 2020 | $2,550 | 80 | Allergan, Inc. ($1,549) |
| 2019 | $22,862 | 130 | Allergan Inc. ($21,339) |
| 2018 | $20,656 | 116 | Allergan Inc. ($19,031) |
| 2017 | $13,094 | 100 | Allergan Inc. ($11,938) |
All Payment Transactions
1,193 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $32.71 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 12/16/2024 | Tris Pharma Inc | — | Food and Beverage | In-kind items and services | $23.90 | General |
| 12/10/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: ADHD | ||||||
| 12/10/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 12/03/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: ADHD | ||||||
| 12/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Travel and Lodging | In-kind items and services | $41.54 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: ADHD | ||||||
| 11/21/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: ADHD | ||||||
| 11/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $9.77 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/19/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $7.16 | General |
| Category: ADHD | ||||||
| 11/19/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $1.57 | General |
| Category: ADHD | ||||||
| 11/18/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/14/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $102.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Noven Therapeutics, LLC | Xelstrym (Drug) | Food and Beverage | In-kind items and services | $9.16 | General |
| Category: ADHD | ||||||
| 11/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.38 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 94 | 245 | $32,865 | $14,086 |
| 2022 | 4 | 82 | 230 | $29,755 | $13,673 |
| 2021 | 3 | 74 | 228 | $29,290 | $15,130 |
| 2020 | 3 | 86 | 237 | $30,530 | $14,642 |
Total Patients
336
Total Services
940
Medicare Billing
$57,531
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 107 | $19,325 | $8,158 | 42.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 30 | 77 | $6,425 | $2,980 | 46.4% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 16 | 32 | $3,200 | $1,855 | 58.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 29 | $3,915 | $1,092 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 101 | $17,345 | $7,424 | 42.8% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 19 | 45 | $4,500 | $2,506 | 55.7% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 22 | 57 | $4,415 | $2,359 | 53.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 27 | $3,495 | $1,385 | 39.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 126 | $20,790 | $10,061 | 48.4% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 26 | 68 | $5,100 | $3,065 | 60.1% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 14 | 34 | $3,400 | $2,004 | 59.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 127 | $20,955 | $8,592 | 41.0% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 23 | 53 | $5,300 | $3,308 | 62.4% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 28 | 57 | $4,275 | $2,743 | 64.2% |
About Dr. Roger Brown, MD
Dr. Roger Brown, MD is a Addiction Medicine healthcare provider based in Mandeville, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538269683.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roger Brown, MD has received a total of $206,240 in payments from pharmaceutical and medical device companies, with $39,910 received in 2024. These payments were reported across 1,193 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($171,475).
As a Medicare-enrolled provider, Brown has provided services to 336 Medicare beneficiaries, totaling 940 services with total Medicare billing of $57,531. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Psychiatry
- Location Mandeville, LA
- Active Since 09/25/2006
- Last Updated 09/04/2019
- Taxonomy Code 2084A0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1538269683
Products in Payments
- VRAYLAR (Drug) $84,168
- QELBREE (Drug) $77,083
- Qelbree (Drug) $26,968
- Azstarys (Drug) $2,631
- REXULTI (Drug) $1,496
- Dyanavel XR (Drug) $1,322
- CAPLYTA (Drug) $799.16
- NEUROSTAR TMS THERAPY (Device) $737.45
- Adzenys XR-ODT (Drug) $652.24
- VYVANSE (Drug) $638.76
- JORNAY PM (Drug) $613.90
- Xelstrym (Drug) $597.55
- AZSTARYS (Drug) $563.50
- Auvelity (Drug) $488.33
- TRINTELLIX (Drug) $481.74
- MYDAYIS (Drug) $394.73
- SPRAVATO (Drug) $383.29
- LATUDA (Drug) $338.23
- VIIBRYD (Drug) $280.00
- QUVIVIQ (Drug) $267.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.